news
AI-designed CDK12/13 inhibitors target resistant cancers
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
List view / Grid view
Clinical Trials
news
Leukaemia cells hit hard by innovative dual-drug approach
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
news
DNA repair genes drive Huntington’s disease, UCLA study finds
A new UCLA study reveals that DNA mismatch repair genes play a crucial role in Huntington’s disease by driving neuronal damage and motor impairments. Targeting these genes, especially Msh3 and Pms1, could offer promising therapeutic avenues for the disease.
news
Restoring the gut: VE303’s strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
article
Promising Alzheimer’s drug earns FDA fast-track designation
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
news
ITM-11 boosts survival in neuroendocrine tumour trial
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
news
Coherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
news
First patient enrolled in fostamatinib trial for sickle cell disease
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
news
New study shows CGM data can predict diabetes complications
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
article
FDA’s Project Optimus: A new era in oncology drug dosing
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
news
LB Pharmaceuticals announces positive schizophrenia trial data
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
news
New painless vaccine technology targets viruses
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
news
New data shows benefits of automated blood exchange for sickle cell disease
New studies highlight the potential of automated blood exchange to improve outcomes for sickle cell disease patients.
article
How AI will reshape pharma in 2025
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
news
Injectable gel targets osteoarthritis pain
Hydrocelin shows promising preclinical results in treating osteoarthritis, offering pain relief and potential joint protection with no observed side effects.